Original ResearchFull Report: Clinical—Alimentary TractPrevention of Dabigatran-Related Gastrointestinal Bleeding With Gastroprotective Agents: A Population-Based Study
Section snippets
Data Source
This study used the electronic medical records of the Clinical Data Analysis and Reporting System (CDARS) of the Hong Kong Hospital Authority (HA), which is the sole public-funded health care provider of Hong Kong. The HA currently serves a population of more than 7 million, managing 42 hospitals, 47 Specialist Out-patient Clinics, and 73 General Out-patient Clinics organized into 7 hospital clusters according to geographic location.11 The HA uses the Clinical Management System (CMS), a
Data Validation
Among the 5041 patients on dabigatran included in this study, 711 patients (14.1%) were from the HKW cluster (Supplementary Figure 1). Of these, we selected all patients who had a diagnosis of GIB (n = 35), all patients with prior history of peptic ulcer/GIB (n = 78), and a random sample of 133 patients (20%) who had AF. As negative controls, we selected a random sample of 66 patients (10%) who did not develop GIB, a random sample of 63 patients (10%) who did not have a prior history of peptic
Discussion
Gastrointestinal bleeding is a major adverse clinical outcome associated with use of the NOACs. In particular, bleeding risk appears to be higher for dabigatran when compared with other NOACs.6 Because there currently is no effective antidote for dabigatran, patients are potentially at a higher risk of uncontrolled GIB compared with warfarin, which can be reversed by vitamin K and fresh-frozen plasma. This would highlight the importance of identifying a preventive strategy for GIB in patients
Conclusions
This study showed that the risk factors of GIB in our patients prescribed dabigatran included ages 75 or older, history of peptic ulcer or GIB, and concomitant use of aspirin. Gastroprotective agents were associated with a reduced risk of GIB in patients on dabigatran. The protective effect seemed to be more for prevention of upper GIB and among those with a prior history of peptic ulcers or GIB. Hence, gastroprotective agents should be considered in high-risk patients taking dabigatran.
Acknowledgment
The authors thank our colleagues in the Department of Pharmacology and Pharmacy of the University of Hong Kong: Ms Celine S. L. Chui for her contribution to initial data retrieval; Mr Kenneth K. C. Man for cross-checking the statistical analysis; and Mrs Lisa Wong for proofreading the manuscript.
References (57)
- et al.
Hemorrhagic gastritis with dabigatran in a patient with renal insufficiency
J Emerg Med
(2013) - et al.
Risk factors for gastrointestinal bleeding associated with low-dose aspirin
Best Pract Res Clin Gastroenterol
(2012) - et al.
Hospitalized patients with atrial fibrillation compared to those included in recent trials on novel oral anticoagulants: a population-based study
Eur J Intern Med
(2013) - et al.
Efficacy and safety of dabigatran etexilate and warfarin in “real-world” patients with atrial fibrillation: a prospective nationwide cohort study
J Am Coll Cardiol
(2013) Differences in peptic ulcer between the East and the West
Gastroenterol Clin North Am
(2009)- et al.
Racial/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation
J Am Coll Cardiol
(2007) Factor V Leiden thrombophilia
Genet Med
(2011)- et al.
Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: a systematic review and meta-analysis
Lancet Neurol
(2010) - et al.
Bleeding rates in Veterans Affairs patients with atrial fibrillation who switch from warfarin to dabigatran
Am J Med
(2014) - et al.
Dabigatran etexilate: a new oral thrombin inhibitor
Circulation
(2011)
Dabigatran versus warfarin in patients with atrial fibrillation
N Engl J Med
Dabigatran versus warfarin in the treatment of acute venous thromboembolism
N Engl J Med
Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial
Eur Heart J
Evaluation of dabigatran bleeding adverse reaction reports in the FDA adverse event reporting system during the first year of approval
Pharmacotherapy
New oral anticoagulants increase risk for gastrointestinal bleeding: a systematic review and meta-analysis
Gastroenterology
European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation
Europace
ACCF/ACG/AHA 2010 Expert Consensus Document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents
Circulation
Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy
Eur Heart J
ADHD drug prescribing trend is increasing among children and adolescents in Hong Kong
J Atten Disord
Influenza-related hospitalizations among children in Hong Kong
N Engl J Med
Dosage effects of histamine-2 receptor antagonist on the primary prophylaxis of non-steroidal anti-inflammatory drug (NSAID)-associated peptic ulcers: a retrospective cohort study
Drug Saf
An investigation of the potential association between retinal detachment and oral fluoroquinolones: a self-controlled case series study
J Antimicrob Chemother
Methylphenidate and the risk of trauma
Pediatrics
Retrospective review of clinical presentations, microbiology, and outcomes of patients with psoas abscess
Hong Kong Med J
Risk of upper gastrointestinal bleeding from different drug combinations
Gastroenterology
Cited by (180)
Management of Anticoagulant and Antiplatelet Agents in Acute Gastrointestinal Bleeding and Prevention of Gastrointestinal Bleeding
2024, Gastrointestinal Endoscopy Clinics of North AmericaNew score for predicting major bleeding in patients with atrial fibrillation using direct oral anticoagulants
2023, International Journal of CardiologyRisk of sepsis and pneumonia in patients initiated on SGLT2 inhibitors and DPP-4 inhibitors
2022, Diabetes and MetabolismRisk factors for anticoagulant-associated gastrointestinal hemorrhage: a systematic review and meta-analysis
2024, Korean Journal of Internal Medicine
Conflicts of interest These authors disclose the following: Esther Chan has received research support from Bristol-Myers Squibb and Janssen (a division of Johnson and Johnson), and Wai K. Leung has received speaker fees from Eisai, Ferring, Menarini, and Takeda, and also serves on the advisory boards of AbbVie, Boehringer-Ingelheim, and Janssen. The remaining authors disclose no conflicts.
Funding This study was supported by the General Research Fund, Research Grants Council, Hong Kong (project number: 17102314).
Author names in bold designate shared co-first authors.
- ∗
Authors share co-first authorship.